Literature DB >> 23690727

Re: Evaluation of small hepatocellular carcinomas with diffusion weighted imaging.

Ferhat Cuce, Guner Sonmez, Emre Karaşahin.   

Abstract

Entities:  

Keywords:  Carcinoma; Diffusion; Hepatocellular; Liver

Mesh:

Year:  2013        PMID: 23690727      PMCID: PMC3655314          DOI: 10.3348/kjr.2013.14.3.544

Source DB:  PubMed          Journal:  Korean J Radiol        ISSN: 1229-6929            Impact factor:   3.500


× No keyword cloud information.
Dear Sir, We are pleased to read the interesting article by Injoong Kim and colleagues (1) in the October 2012 issue of Korean Journal of Radiology. The authors examined the the histologic characteristics of hepatocellular carcinomas (HCCs) showing atypical enhancement patterns which would definitely add to the current literature. They found that HCCs showing atypical dynamic enhancement are usually smaller than typical HCCs. Since we have special interest on the diffusion magnetic resonance imaging (MRI) subject (2), we want to contribute information about the radiological evaluation of the small HCC nodules. HCC is the most common primary liver cancer and generally develops secondarily to chronic hepatitis or cirrhosis in elderly individuals. In the differential diagnosis of hepatocellular nodules up to 1 cm in diameter in the cirrhotic liver, regenerative nodules, low or high grade dysplastic nodules and early or progressed HCC should be considered. This poses a difficulty for the radiologist, especially in differentiation of dysplasia or HCC. Diffusion weighted imaging (DWI) is virtually useless in detecting and characterizing borderline lesions in cirrhosis but ADC measurement of DWI may estimate the tumor grade of these HCCs since ADC tends to decrease in the order of well, moderately and poorly differentiated HCCs (3). Second, it was reported that if the liver function is normal, T2 weighted images may have the highest sensitivity among the other imaging parameters for differentiating HCCs 1 cm or smaller from benign hypervasculer lesions (4). Also, in this study (4) it was found that the combination of T2 sequence and DWI have high specificity in detection of HCC which is important - especially in elderly patients - against the risk of using contrast material. Third, due to the different histopathological features of liver parenchyme or HCC, DWI is useful in determining hepatic metastases commonly seen in elderly people and in atypical hemangioma cases which are defined by hypervasculer enhancement on the arterial phase (3). Lastly, after invasive treatments (transcatheter arterial chemoembolization, thermal ablation, partial hepatectomy and irradiation) of HCCs 1 cm or smaller, DWI helps to detect hypervascular intrahepatic HCC metastases or regional HCC recurrence by excluding the interference of early enhancing pseudolesions due to the postoperative arterioportal shunting (3).
  4 in total

1.  Value of diffusion-weighted MRI in the differentiation of benign and malign breast lesions.

Authors:  G Sonmez; F Cuce; H Mutlu; M Incedayi; E Ozturk; O Sildiroglu; M Velioglu; C C Bashekim; E Kizilkaya
Journal:  Wien Klin Wochenschr       Date:  2011-09-18       Impact factor: 1.704

2.  Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging.

Authors:  Ji-Eun Kim; Seong Hyun Kim; Soon Jin Lee; Hyunchul Rhim
Journal:  AJR Am J Roentgenol       Date:  2011-06       Impact factor: 3.959

3.  Histologic characteristics of hepatocellular carcinomas showing atypical enhancement patterns on 4-phase MDCT examination.

Authors:  Injoong Kim; Myeong-Jin Kim
Journal:  Korean J Radiol       Date:  2012-08-28       Impact factor: 3.500

Review 4.  Diffusion/perfusion MR imaging of the liver: practice, challenges, and future.

Authors:  Masayuki Kanematsu; Satoshi Goshima; Haruo Watanabe; Hiroshi Kondo; Hiroshi Kawada; Yoshifumi Noda; Noriyuki Moriyama
Journal:  Magn Reson Med Sci       Date:  2012       Impact factor: 2.471

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.